Search Results - (Author, Cooperation:J. Hoon)

Showing 1 - 5 results of 5, query time: 0.13s Refine Results
  1. 1
    Staff View
    Publication Date:
    2011-07-22
    Publisher:
    Nature Publishing Group (NPG)
    Print ISSN:
    0028-0836
    Electronic ISSN:
    1476-4687
    Topics:
    Biology
    Chemistry and Pharmacology
    Medicine
    Natural Sciences in General
    Physics
    Keywords:
    Escherichia coli/genetics ; Genome, Bacterial/*genetics ; Genome, Human/*genetics ; Genomics/*instrumentation/*methods ; Humans ; Light ; Male ; Rhodopseudomonas/genetics ; *Semiconductors ; Sequence Analysis, DNA/*instrumentation/*methods ; Vibrio/genetics
    Published by:
    http://www.nature.com/

    Latest Papers from Table of Contents or Articles in Press
  2. 2
    Vanhove, T., de Jonge, H., de Loor, H., Oorts, M., de Hoon, J., Pohanka, A., Annaert, P., Kuypers, D. R. J.
    The American Society for Pharmacology and Experimental Therapeutics (ASPET)
    Published 2018
    Staff View
    Publication Date:
    2018-10-13
    Publisher:
    The American Society for Pharmacology and Experimental Therapeutics (ASPET)
    Print ISSN:
    0090-9556
    Electronic ISSN:
    1521-009X
    Topics:
    Chemistry and Pharmacology
    Medicine
    Published by:
    http://www.aspet.org/

    Latest Papers from Table of Contents or Articles in Press
  3. 3
    Staff View
    ISSN:
    1365-2036
    Source:
    Blackwell Publishing Journal Backfiles 1879-2005
    Topics:
    Medicine
    Notes:
    Background : Aspirin is widely used as an anti-thrombotic drug; however, it has been suggested that enteric-coated formulations of aspirin may be less bioavailable and less effective as anti-thrombotic agents.Aim : To assess the effect of a formulation of enteric-coated, low-dose (81 mg) aspirin on serum generated thromboxane B2 and platelet aggregation in healthy subjects.Methods : Twenty-four subjects participated in a double-blind, randomized, placebo-controlled, parallel-group, multiple-dose study. Twelve subjects in each of two groups received a daily oral dose of enteric-coated aspirin (81 mg) or matching placebo for 7 days. Serum thromboxane B2 and platelet aggregation (using 1 mm arachidonic acid and 1 µg/mL collagen as agonists) were measured 1–3 days prior to day 1, on day 1 (prior to therapy) and 4 h after the last dose on day 7.Results : After seven daily doses of enteric-coated aspirin, the mean percentage inhibition from baseline of ex vivo generated serum thromboxane B2 was 97.4%, compared with a 7.8% increase after placebo treatment. The mean percentage inhibition of arachidonic acid- and collagen-induced platelet aggregation was 97.9% and 70.9%, respectively, following enteric-coated aspirin, compared with − 1.0% and 2.7%, respectively, after placebo.Conclusions : The anti-platelet effects of multiple, daily, low-dose aspirin (as assessed by inhibition of serum thromboxane B2 and platelet aggregation) are not adversely affected by enteric coating.
    Type of Medium:
    Electronic Resource
    URL:
    http://dx.doi.org/10.1046/j.1365-2036.2002.01332.x

    Articles: DFG German National Licenses
  4. 4
    Soo, H.L. ; Kyung-Hoon, J. ; Dong, S.L.

    Amsterdam : Elsevier
    Staff View
    ISSN:
    0039-9140
    Source:
    Elsevier Journal Backfiles on ScienceDirect 1907 - 2002
    Topics:
    Chemistry and Pharmacology
    Type of Medium:
    Electronic Resource
    URL:
    http://linkinghub.elsevier.com/retrieve/pii/0039-9140(89)80182-1

    Articles: DFG German National Licenses
  5. 5
    Staff View
    ISSN:
    1432-1041
    Keywords:
    Key words Nebivolol ; β-adrenoceptor blockers ; β1-selectivity ; pharmacological properties
    Source:
    Springer Online Journal Archives 1860-2000
    Topics:
    Chemistry and Pharmacology
    Medicine
    Notes:
    Abstract Objectives: The aims of the present study were to determine (1) the β1-blocking potency and (2) the β1-adrenoceptor selectivity of nebivolol in man after repeated dosing (7 days) compared with that after a single oral intake and with that after atenolol for 7 days. In addition, it was investigated whether (3) nebivolol has α1-blocking properties which might at least in part explain the vasodilating property of the compound. Methods: Twelve healthy subjects were randomized in an open, two-way cross-over study. β1-Blocking potency and β1-adrenoceptor selectivity of nebivolol 5 mg once daily (o.d.) were compared with those of atenolol at three doses (25, 50 and 100 mg) o.d. Measurements were performed after 1 and 7 days of drug intake. β1-Adrenoceptor potency was assessed by the percentage decrease in exercise-induced tachycardia (ΔEIT) during β-blockade. β1-Selectivity of nebivolol and atenolol were investigated using the heart rate response to isoprenaline at equipotent β1-blocking dosages of both drugs. α1-Blockade of nebivolol was measured using the phenylephrine dose-response test. Results: ΔEIT after a single oral dose of nebivolol 5 mg (10%) was significantly smaller than after nebivolol 5 mg o.d. for 7 days (15%). After 1 week of treatment no difference was seen in ΔEIT between nebivolol 5 mg o.d. and atenolol 25 mg o.d. (16%). At these dosages the suppression in isoprenaline-induced tachycardia by both drugs did not differ (CD20 ratio 1.7). In contrast to atenolol 25 mg, after 1 week of nebivolol 5 mg o.d., blood pressure decreased. This decrease averaged 10% and – like in a study with hypertensive patients – was similar with that after atenolol 100 mg o.d. None of the phenylephrine test parameters changed from pre-study values after nebivolol. Conclusions: β1-Blockade of nebivolol 5 mg is larger after repeated dosing than after a single oral intake. After once daily repeated dosing nebivolol 5 mg and atenolol 25 mg are equipotent in β1-antagonism. No difference in β1-selectivity is observed between the two drugs. Nebivolol has no additional α1-blocking property, which may at least in part explain its vasodilating effect.
    Type of Medium:
    Electronic Resource
    URL:
    http://dx.doi.org/10.1007/s002280050217

    Articles: DFG German National Licenses